{"Title": "The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours", "Year": 2019, "Source": "Endocr.-Relat. Cancer", "Volume": "26", "Issue": 9, "Art.No": null, "PageStart": null, "PageEnd": null, "CitedBy": 6, "DOI": "10.1530/ERC-19-0175", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85070848398&origin=inward", "Abstract": "\u00a9 2019 Society for Endocrinology.Neuroendocrine neoplasms (NENs) are a relatively rare group of heterogeneous tumours originating from neuroendocrine cells found throughout the body.Pancreatic NENs (PanNENs) are the second most common pancreatic malignancy accounting for 1-3% of all neoplasms developing in the pancreas.Despite having a low background mutation rate, driver mutations in MEN1, DAXX/ATRX and mTOR pathway genes (PTEN, TSC1/2) are implicated in disease development and progression.Their increased incidence coupled with advances in sequencing technologies has reignited the interest in PanNEN research and has accelerated the acquisition of molecular data.Studies utilising such technological advances have further enriched our knowledge of PanNENs biology through novel findings, including higher-than-expected presence of germline mutations in 17% of sporadic tumours of no familial background, identification of novel mutational signatures and complex chromosomal rearrangements and a dysregulated epigenetic machinery.Integrated genomic studies have progressed the field by identifying the synergistic action between different molecular mechanisms, while holding the promise for deciphering disease heterogeneity.Although our understanding is far from being complete, these novel findings have provided the optimism of shaping the future of PanNEN research, ultimately leading to an era of precision medicine for NETs.He re, we recapitulate the existing knowledge on pancreatic neuroendocrine tumours (PanNETs) and discuss how recent, novel findings have furthered our understanding of these complex tumours.", "AuthorKeywords": ["Alternative lengthening of telomeres", "ATRX", "Brca2", "Chek2", "Chromatin remodelling", "DAXX", "MEN1", "Mtor", "Mutyh", "Pancreatic neuroendocrine tumour"], "IndexKeywords": ["Epigenesis, Genetic", "Humans", "Neuroendocrine Tumors", "Pancreatic Neoplasms"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 0, "EID": "2-s2.0-85070848398", "SubjectAreas": [["Endocrinology, Diabetes and Metabolism", "MEDI", "2712"], ["Oncology", "MEDI", "2730"], ["Endocrinology", "BIOC", "1310"], ["Cancer Research", "BIOC", "1306"]], "AuthorData": {"19934115400": {"Name": "Pipinikas C.P.", "AuthorID": "19934115400", "AffiliationID": "60022148", "AffiliationName": "Medical Genomics Laboratory, University College London Cancer Institute"}, "57204930626": {"Name": "Berner A.M.", "AuthorID": "57204930626", "AffiliationID": "60022148", "AffiliationName": "Medical Genomics Laboratory, University College London Cancer Institute"}, "56814902900": {"Name": "Sposito T.", "AuthorID": "56814902900", "AffiliationID": "60022148", "AffiliationName": "Medical Genomics Laboratory, University College London Cancer Institute"}, "6603079245": {"Name": "Thirlwell C.", "AuthorID": "6603079245", "AffiliationID": "60032819", "AffiliationName": "Neuroendocrine Tumour Unit and Department of Oncology, Royal Free Hospital"}}}